Cargando…

The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes

OBJECTIVE: To examine the gut microbiota in individuals with and without pediatric‐onset multiple sclerosis (MS). METHODS: We compared stool‐derived microbiota of Canadian Pediatric Demyelinating Disease Network study participants ≤21 years old, with MS (disease‐modifying drug [DMD] exposed and naïv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tremlett, Helen, Zhu, Feng, Arnold, Douglas, Bar‐Or, Amit, Bernstein, Charles N., Bonner, Christine, Forbes, Jessica D., Graham, Morag, Hart, Janace, Knox, Natalie C., Marrie, Ruth Ann, Mirza, Ali I., O’Mahony, Julia, Van Domselaar, Gary, Yeh, E. Ann, Zhao, Yinshan, Banwell, Brenda, Waubant, Emmanuelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670321/ https://www.ncbi.nlm.nih.gov/pubmed/34889081 http://dx.doi.org/10.1002/acn3.51476

Ejemplares similares

Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases
por: Liang, Geoffrey, et al.
Publicado: (2022)

Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes
por: Fadda, Giulia, et al.
Publicado: (2021)

Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes
por: Waters, Patrick, et al.
Publicado: (2019)

High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study
por: Marrie, Ruth Ann, et al.
Publicado: (2019)

The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents
por: O’Mahony, Julia, et al.
Publicado: (2022)

Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life
por: O’Mahony, Julia, et al.
Publicado: (2023)

Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course
por: Nourbakhsh, Bardia, et al.
Publicado: (2018)

Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria
por: Fadda, Giulia, et al.
Publicado: (2022)

Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes
por: Longoni, Giulia, et al.
Publicado: (2018)

A surface‐in gradient of thalamic damage evolves in pediatric multiple sclerosis
por: Fadda, Giulia, et al.
Publicado: (2019)

A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease?
por: Forbes, Jessica D., et al.
Publicado: (2019)

Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls
por: Tremlett, Helen, et al.
Publicado: (2016)

Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders
por: Bells, Sonya, et al.
Publicado: (2022)

Preventing Multiple Sclerosis: The Pediatric Perspective
por: Hardy, Duriel, et al.
Publicado: (2022)

Treatment Approaches for MOG-Ab-Associated Demyelination in Children
por: Hacohen, Yael, et al.
Publicado: (2019)

A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist?
por: Forbes, Jessica D., et al.
Publicado: (2018)

Assessment of Inter-Laboratory Variation in the Characterization and Analysis of the Mucosal Microbiota in Crohn’s Disease and Ulcerative Colitis
por: Szamosi, Jake C., et al.
Publicado: (2020)

Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits
por: Graf, Jonas, et al.
Publicado: (2022)

Neuroinflammatory and Demyelinating Disorders of Childhood
por: Nouri, Maryam Nabavi, et al.
Publicado: (2020)

Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children
por: Razaz, Neda, et al.
Publicado: (2016)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
por: Graf, Jonas, et al.
Publicado: (2023)

Microbiome-Mediated Immune Signaling in Inflammatory Bowel Disease and Colorectal Cancer: Support From Meta-omics Data
por: Pratt, Molly, et al.
Publicado: (2021)

Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood
por: Bruijstens, Arlette L, et al.
Publicado: (2022)

Disease-modifying drugs for multiple sclerosis and subsequent health service use
por: Ng, Huah Shin, et al.
Publicado: (2021)

Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis
por: O'Mahony, Julia, et al.
Publicado: (2022)

Sex and age differences in the Multiple Sclerosis prodrome
por: Yusuf, Fardowsa L. A., et al.
Publicado: (2022)

Children and adolescents adjustment to parental multiple sclerosis: a systematic review
por: Razaz, Neda, et al.
Publicado: (2014)

Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease
por: Sacco, Simone, et al.
Publicado: (2023)

Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children
por: Longoni, Giulia, et al.
Publicado: (2014)

Memory, processing of emotional stimuli, and volume of limbic structures in pediatric-onset multiple sclerosis
por: Fabri, Tracy L., et al.
Publicado: (2021)

A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada
por: McKay, Kyla, et al.
Publicado: (2017)

Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis
por: Longoni, Giulia, et al.
Publicado: (2022)

Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
por: Arnold, Douglas L, et al.
Publicado: (2020)

Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
por: Deiva, Kumaran, et al.
Publicado: (2020)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population
por: Ng, Huah Shin, et al.
Publicado: (2022)

The Gut Microbiota in Immune-Mediated Inflammatory Diseases
por: Forbes, Jessica D., et al.
Publicado: (2016)

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG
por: Waubant, Emmanuelle, et al.
Publicado: (2019)

Five-minute Apgar score as a marker for developmental vulnerability at 5 years of age
por: Razaz, Neda, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ggge6if4des5e1r0dbfh6b3a0j